Psoriatic Arthritis
4 competing products in clinical development for Psoriatic Arthritis.
Pipeline by Phase
Phase 21
Phase 32
Approved1
All Products (4)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ixekizumab + Adalimumab | Eli Lilly | Approved | Completed | 85 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | Completed | 77 |
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | Active | 77 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | Terminated | 47 |